Meta-Analysis of Cutaneous Adverse Reactions Induced by Dabrafenib Combined with Trametinib in the Treatment of Melanoma

Abstract

Abstract:

〔Abstract〕 Objective： To systematically evaluate the incidence of cutaneous adverse reactions induced by dabrafenib combined with trametinib in the treatment of melanoma. Methods： PubMed， EMbase， Cochrane Library， Web of Science， CNKI， VIP， Wanfang and China Biomedical Literature Database were searched by computer， and relevant published studies at home and abroad were collected. The retrieval period was from the establishment of the database to December 2020. Stata 15.1 software was used to calculate the incidence of cutaneous adverse reactions. RevMan 5.3 software was used to assess the relative risk（RR） for all grades of cutaneous adverse reactions. Results： A total of 10 studies involving 2 623 patients were included. The incidence of cutaneous adverse reactions of all grades in the treatment of melanoma with dabrafenib combined with trametinib were as follows：exanthem 22%［95%CI（0.19， 0.26）］， pruritus 10%［95%CI（0.08， 0.11）］， hyperkeratosis 7%［95%CI（0.04， 0.10）］， alopecia 5%［95%CI（0.04， 0.07）］， cutaneous papilloma 1%［95%CI（0.01， 0.03）］， acneiform dermatitis 10%［95%CI（0.06， 0.14）］， cutaneous squamous cell carcinoma 2%［95%CI（0.00， 0.04）］， dry skin 10% ［95%CI （0.08， 0.12）］ and erythema 11%［95%CI（0.09， 0.13）］. Compared with BRAF inhibitor alone， dabrafenib combined with trametinib reduced the incidence of pruritus， hyperkeratosis， alopecia， cutaneous papilloma， and cutaneous squamous cell carcinoma（P<0.05）. Conclusion： Exanthem is a common cutaneous adverse reaction in patients with melanoma treated with darafenib combined with trametinib. Compared with BRAF inhibitor alone， the combination drug significantly reduced the occurrence of cutaneous adverse reactions.

Key words:

"> ">〔Key words">〕 melanoma">； dabrafenib">； trametinib">； cutaneous adverse reactions">； Meta-analysis

CLC Number:

Wang Ruihang, Liu Xiaobo, Liao Ｓi, Hua Peng.

Meta-Analysis of Cutaneous Adverse Reactions Induced by Dabrafenib Combined with Trametinib in the Treatment of Melanoma [J]. Journal of Dali University, 2022, 7(4): 12-20.

References

〔1〕 DIRK S， ALEXANDER C J V A， CAROLA B， et al. Melanoma〔J〕.Lancet，2018，392（10151）：971-984.

〔2〕 Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma〔J〕.Cell，2015，161（7）：1681-1696.

〔3〕 LONG G V， STROYAKOVSKIY D， GOGAS H， et al. Dabrafenib and Trametinib versus Dabrafenib and Placebo for Val600 BRAF-Mutant Melanoma： A Multicentre， Doubleblind， Phase 3 Randomised Controlled Trial〔J〕.Lancet，2015，386（9992）：444-451.

〔4〕 ROBERT C， KARASZEWSKA B， SCHACHTER J， et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib〔J〕.N Engl J Med，2015，372（1）：30-39.

〔5〕 LONG G V， HAUSCHILD A， SANTINAMI M， et al. Adjuvant Dabrafenib plus Trametinib in Stage Ⅲ BRAF-Mutated Melanoma〔J〕.N Engl J Med，2017，377（19）：1813-1823.

〔6〕 ALGAZI A P， OTHUS M， DAUD A I， et al. Continuous versus Intermittent BRAF and MEK Inhibition in Patients with BRAF-Mutated Melanoma： A Randomized Phase 2 Trial〔J〕.Nat Med，2020，26（10）：1564-1568.

〔7〕 FLAHERTY K T， INFANTE J R， DAUD A， et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations〔J〕.N Engl J Med，2012，367（18）：1694-1703.

〔8〕 ASCIERTO P A， FERRUCCI P F， FISHER R， et al. Dabrafenib， Trametinib and Pembrolizumab or Placebo in BRAF-Mutant Melanoma〔J〕.Nat Med，2019，25（6）：941-946.

〔9〕 LARKIN J， ASCIERTO P A， DRNO B， et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melano-ma〔J〕.N Engl J Med，2014，371（20）：1867-1876.

〔10〕 DUMMER R， ASCIERTO P A， GOGAS H J， et al. Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAF-Mutant Melanoma （COLUMBUS）： A Multicentre， Open-Label， Randomised Phase 3 Trial〔J〕.Lancet Oncol，2018，19（5）：603-615.

〔11〕 KANDOLF S L， PERIS K， HAUSCHILD A， et al. More than 5 000 Patients with Metastatic Melanoma in Europe per Year Do Not Have Access to Recommended First-Line Innovative Treatments〔J〕.Eur J Cancer，2017，75：313-322.

〔12〕 JADAD A R， MOORE R A， CARROLL D， et al. Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary？〔J〕. Control Clin Trials，1996，17（1）：1-12.

〔13〕 STANG A. Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses〔J〕.Eur J Epidemiol，2010，25（9）：603-605.

〔14〕 SCHREUER M， JANSEN Y， PLANKEN S， et al. Combination of Dabrafenib plus Trametinib for BRAF and MEK Inhibitor Pretreated Patients with Advanced BRAFV600-Mutant Melanoma： An Open-Label， Single Arm， Dual-Centre， Phase 2 Clinical Trial〔J〕.Lancet Oncol，2017，18（4）：464-472.

〔15〕 DAVIES M A， SAIAG P， ROBERT C， et al. Dabrafenib plus Trametinib in Patients with BRAFV600-Mutant Melanoma Brain Metastases （COMBI-MB）： A Multicentre， Multicohort， Open-Label， Phase 2 Trial〔J〕.Lancet Oncol，2017，18（7）：863-873.

〔16〕 JOHNSON D B， FLAHERTY K T， WEBER J S， et al. Combined BRAF （Dabrafenib） and MEK Inhibition （Trame-tinib） in Patients with BRAFV600-Mutant Melanoma Experiencing Progression with Single-agent BRAF Inhi-bitor〔J〕.J Clin Oncol，2014，32（33）：3697-3704.

〔17〕 SI L， ZHANG X S， SHIN S J， et al. Open-Label， Phase Ⅱa Study of Dabrafenib plus Trametinib in East Asian Patients with Advanced BRAF V600-Mutant Cutaneous Melanoma〔J〕.Eur J Cancer，2020，135：31-38.

〔18〕 SINHA R， LARKIN J， GORE M， et al. Cutaneous Toxicities Associated with Vemurafenib Therapy in 107 Patients with BRAF V600E Mutation-Positive Metastatic Melanoma， Including Recognition and Management of Rare Presentations〔J〕.Br J Dermatol，2015，173（4）：1024-1031.

〔19〕 PENG C， JIE X L. The Incidence and Risk of Cutaneous Toxicities Associated with Dabrafenib in Melanoma Patients： A Systematic Review and Meta-Analysis〔J〕.Euro J Hosp Pharm，2020，28（4）：182-189.

〔20〕 BOADA A， CARRERA C， SEGURA S， et al. Cutaneous Toxicities of New Treatments for Melanoma〔J〕.Clin Transl Oncol，2018，20（11）：1373-1384.

〔21〕 GNANENDRAN S S， TURNER L M， MILLER J A，et al. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors〔J〕.Curr Treat Options Oncol，2020，21（4）：29.

〔22〕 ZIMMER L， LIVINGSTONE E， HILLEN U， et al. Panniculitis with Arthralgia in Patients with Melanoma Treated with Selective BRAF Inhibitors and Its Manage-ment〔J〕.Arch Dermatol，2012，148（3）：357-361.

〔23〕 MCLELLAN B， KERR H. Cutaneous Toxicities of the Multikinase Inhibitors Sorafenib and Sunitinib〔J〕.Derma-tol Ther，2011，24（4）：396-400.

〔24〕 SACHSE M M， WAGNER G. Clearance of BRAF Inhibitor-Associated Keratoacanthomas by Systemic Retinoids〔J〕.Br J Dermatol，2014，170（2）：475-477.

〔25〕 WU J H， COHEN D N， RADY P L， et al. BRAF Inhibitor-Associated Cutaneous Squamous Cell Carci-noma： New Mechanistic Insight， Emerging Evidence for Viral Involvement and Perspectives on Clinical Manage-ment〔J〕.Br J Dermatol，2017，177（4）：914-923.

〔26〕 BELOW J， HOMEY B， GERBER P A. Kutane Nebenwir-

kungen Zielgerichteter Onkologischer Arzneimittel〔J〕.Hautarzt，2017，68（1）：12-18.

〔27〕 FAJE A T， LAWRENCE D， FLAHERTY K， et al. High-Dose Glucocorticoids for the Treatment of Ipilimu-mab-Induced Hypophysitis Is Associated with Reduced Survival in Patients with Melanoma〔J〕.Cancer，2018，124（18）：3706-3714.

[1]	Yang Limin. Independent Number and Independent Polynomial of Complete Product of Graph [J]. Journal of Dali University, 2023, 8(6): 1-8.
[2]	Zhou Bin. Research on the Solution of Pure Integer Programming Problem Based on Number Theory [J]. Journal of Dali University, 2023, 8(6): 14-19.
[3]	Chen Li, Zhu Xingwen, Zhang Chaoyuan. The High-Precision Runge-Kutta Method for Solving Two-Dimensional Acoustic Wave Equation [J]. Journal of Dali University, 2023, 8(6): 20-23.
[4]	Wu Guifeng, Hu Fa, Zeng Xin, Yang Dengqi, Li Xiaowei. MV-Raft： A New Consensus Algorithm forAllianceChain Based on Multidimensional Vectors [J]. Journal of Dali University, 2023, 8(6): 24-32.
[5]	Cui Maohuan, Rao Dingqi. Diversity and Faunal Characteristics of Amphibians and Reptiles in Lanping Yunling Provincial Nature Reserve [J]. Journal of Dali University, 2023, 8(6): 61-68.
[6]	Li Jia, Yang Yingfei. A Dynamic Study on Students' Physical Fitness inDaliUniversity [J]. Journal of Dali University, 2023, 8(6): 69-74.
[7]	Tang Liang, Lu Jingnan, Jiang Haifeng, Xue Jiuyang. Executive Political Connections， Changes in Environmental Regulatory Modes， and Corporate Environmental Investment [J]. Journal of Dali University, 2023, 8(6): 79-87.
[8]	Ma Chenyu, Liu Chaorui, Lü Jianguo, Zhou Dongyan, Ye Zhilan. Analysis of Yield and Agronomic Traits of Maize Hybrids Bred from Inbred Line 2408 [J]. Journal of Dali University, 2023, 8(6): 88-94.
[9]	Xiong Kai, Xiao Tianbao, Zeng Lian, Luo Zicheng, Yang Tao, Yang Shengbang. Therapeutic Effect of Miao Medicine Rubus pluribracteatus on Mice with Ulcerative Colitis [J]. Journal of Dali University, 2023, 8(4): 1-6.
[10]	Meng Dong, Li Ya, Wang Chongjuan, Tian Yong, Tian Yuncai, Wu Mingyi. Content Determination and Methodological Validation of Snail Glycosaminoglycan [J]. Journal of Dali University, 2023, 8(4): 7-12.
[11]	Wang Jinyu, Zhou Longlong, Wang Xuechang, Li Xiaodong, Geng Shuqiong, Xia Conglong. Investigation on the Mechanism of Lemai Granules in the Treatment of Vascular Dementia Based on Network Pharmacology and Molecular Docking [J]. Journal of Dali University, 2023, 8(4): 13-21.
[12]	Huang Shan, Jin Liquan, Yu Yu, Huang Ji, Zhang Junhua, Chen Yiming. Expression of SOX9 in the Directed Differentiation of Mouse Hepatic Oval Cell into Biliary Epithelial Cells [J]. Journal of Dali University, 2023, 8(4): 22-27.
[13]	Zhao Chunjing, Chen Weiguo, Bai li, Wu Youcong. Effects of Periplaneta americana Extract CⅡ-3 on the Biofilm Formation of Candida albicans [J]. Journal of Dali University, 2023, 8(4): 28-33.
[14]	Bai Zongkai, Lü Neng, Liu Runhua, Luo Yuanxi, Wu Qiuyue, Xu Jing, Wu Youcong. Investigation on the Carrier Rate and Antifungal Susceptibility of Yeast Species Isolated from External Urethral Meatus of Healthy College Students [J]. Journal of Dali University, 2023, 8(4): 34-38.
[15]	Gao Wenyu, Zeng Rong, Xu Mengna, Zhang Yuanyuan. Study on the Correlation between Polymorphism of EPAS1 Gene rs1868092 and High Altitude Polycythemia in Tibetan Population [J]. Journal of Dali University, 2023, 8(4): 39-42.